<SEC-DOCUMENT>0000950170-24-124626.txt : 20241112
<SEC-HEADER>0000950170-24-124626.hdr.sgml : 20241112
<ACCEPTANCE-DATETIME>20241112080635
ACCESSION NUMBER:		0000950170-24-124626
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		12
CONFORMED PERIOD OF REPORT:	20241112
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20241112
DATE AS OF CHANGE:		20241112

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			HERON THERAPEUTICS, INC. /DE/
		CENTRAL INDEX KEY:			0000818033
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				942875566
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33221
		FILM NUMBER:		241443561

	BUSINESS ADDRESS:	
		STREET 1:		4242 CAMPUS POINT COURT, SUITE 200
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		8582514400

	MAIL ADDRESS:	
		STREET 1:		4242 CAMPUS POINT COURT, SUITE 200
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AP PHARMA INC /DE/
		DATE OF NAME CHANGE:	20010511

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ADVANCED POLYMER SYSTEMS INC /DE/
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>hrtx-20241112.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2024-11-11T19:30:20.7121+00:00 -->
<!-- Copyright (c) 2024 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:hrtx="http://www.herontx.com/20241112" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:utr="http://www.xbrl.org/2009/utr">
 <head>
  <title>8-K</title>
  <meta http-equiv="Content-Type" content="text/html"/>
 </head>
 <body style="margin: auto!important;padding: 8px;line-height: 1;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_a9eefa1a-66f8-4a82-98af-8792d0ab387c" name="dei:AmendmentFlag" contextRef="C_170e093a-3fe7-415b-a742-0458650cdf6a" format="ixt:fixed-false">false</ix:nonNumeric><ix:nonNumeric id="F_29e16f69-ba01-4e64-9cbe-731e8f4768ad" name="dei:EntityCentralIndexKey" contextRef="C_170e093a-3fe7-415b-a742-0458650cdf6a">0000818033</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="hrtx-20241112.xsd"/></ix:references><ix:resources><xbrli:context id="C_170e093a-3fe7-415b-a742-0458650cdf6a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000818033</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-12</xbrli:startDate><xbrli:endDate>2024-11-12</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>
  <div style="z-index:-3;min-height:0.5in;position:relative;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1.5pt double #000000;text-align:left;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">UNITED STATES</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">SECURITIES AND EXCHANGE COMMISSION</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Washington, D.C. 20549</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:37.067%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid #000000;margin-right:37.065%;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">FORM </span><span style="font-size:18pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a53982b8-b9b9-4308-b491-a8125b126047" contextRef="C_170e093a-3fe7-415b-a742-0458650cdf6a" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">8-K</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:37.067%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid #000000;margin-right:37.065%;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">CURRENT REPORT</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to Section 13 or 15(d)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">of the Securities Exchange Act of 1934</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Date of Report (Date of earliest event reported): </span><span style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3fc7c041-4614-4c22-9b10-fa7c190f07d1" contextRef="C_170e093a-3fe7-415b-a742-0458650cdf6a" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">November 12, 2024</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:37.067%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid #000000;margin-right:37.065%;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:24pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ec68f443-4c4e-4005-955f-5f6fcc03b9e0" contextRef="C_170e093a-3fe7-415b-a742-0458650cdf6a" name="dei:EntityRegistrantName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:24pt;font-family:Times New Roman;min-width:fit-content;">Heron Therapeutics, Inc.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:24pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(Exact name of registrant as specified in its charter)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:37.067%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid #000000;margin-right:37.065%;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:30.58%;box-sizing:content-box;"/>
    <td style="width:1.32%;box-sizing:content-box;"/>
    <td style="width:37.24%;box-sizing:content-box;"/>
    <td style="width:1.32%;box-sizing:content-box;"/>
    <td style="width:29.54%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_c44b301e-f52b-471d-9aac-3be382b815fb" contextRef="C_170e093a-3fe7-415b-a742-0458650cdf6a" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_dda70719-5ce2-4b69-ba05-32be4b44f4b1" contextRef="C_170e093a-3fe7-415b-a742-0458650cdf6a" name="dei:EntityFileNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">001-33221</span></ix:nonNumeric></span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_6b8691e5-71d8-4c1e-8aba-fb8035160817" contextRef="C_170e093a-3fe7-415b-a742-0458650cdf6a" name="dei:EntityTaxIdentificationNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">94-2875566</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(State or other jurisdiction</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">of incorporation)</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Commission</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">File Number)</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(I.R.S. Employer</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Identification No.)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:55.52%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:43.48%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_2a0cc5e4-2e77-465f-80ae-422662f9136a" contextRef="C_170e093a-3fe7-415b-a742-0458650cdf6a" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">4242 Campus Point Court</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">, </span><span><ix:nonNumeric id="F_0ee9f905-8e14-4dc9-a96a-c5bf4411bb0b" contextRef="C_170e093a-3fe7-415b-a742-0458650cdf6a" name="dei:EntityAddressAddressLine2"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Suite 200</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">, </span><span><ix:nonNumeric id="F_a629c00e-b2f0-4a11-ae77-c4b6df7f683b" contextRef="C_170e093a-3fe7-415b-a742-0458650cdf6a" name="dei:EntityAddressCityOrTown"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">San Diego</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">, </span><span><ix:nonNumeric id="F_2ea9cd90-cf58-45da-bd94-b41d789b13f7" contextRef="C_170e093a-3fe7-415b-a742-0458650cdf6a" name="dei:EntityAddressStateOrProvince"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">CA</span></ix:nonNumeric></span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_4436cd56-352c-48c1-a9db-40679cd8f08b" contextRef="C_170e093a-3fe7-415b-a742-0458650cdf6a" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">92121</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Address of principal executive offices)</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Zip Code)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Registrant&#8217;s telephone number, including area code </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5a2485df-ce39-4c03-ae61-530057a17131" contextRef="C_170e093a-3fe7-415b-a742-0458650cdf6a" name="dei:CityAreaCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(858)</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_cfea956f-24df-46a0-8b06-f46ba61385ee" contextRef="C_170e093a-3fe7-415b-a742-0458650cdf6a" name="dei:LocalPhoneNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">251-4400 </span></ix:nonNumeric></span><span style="font-size:10pt;font-family:Times New Roman;"></span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">N/A</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(Former name or former address, if changed since last report)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:37.067%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid #000000;margin-right:37.065%;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4%;box-sizing:content-box;"/>
    <td style="width:96%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_00511739-ded9-4c8e-a1f0-1c028f1eea5a" contextRef="C_170e093a-3fe7-415b-a742-0458650cdf6a" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4%;box-sizing:content-box;"/>
    <td style="width:96%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_ec98dc2a-8064-4d08-98de-9f74cfc7c81e" contextRef="C_170e093a-3fe7-415b-a742-0458650cdf6a" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4%;box-sizing:content-box;"/>
    <td style="width:96%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_0f8b651a-e4d4-48d8-b458-d555b0a7f3bf" contextRef="C_170e093a-3fe7-415b-a742-0458650cdf6a" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4%;box-sizing:content-box;"/>
    <td style="width:96%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_eaf9580d-a108-4aa9-8625-6bb2fb875c06" contextRef="C_170e093a-3fe7-415b-a742-0458650cdf6a" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:39.92%;box-sizing:content-box;"/>
    <td style="width:1.32%;box-sizing:content-box;"/>
    <td style="width:22.6%;box-sizing:content-box;"/>
    <td style="width:1.34%;box-sizing:content-box;"/>
    <td style="width:34.82%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid #000000;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Title of each class</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid #000000;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Trading Symbol(s)</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid #000000;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Name of each exchange on which registered</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_12dff7c3-d758-4349-a72b-310336124dbc" contextRef="C_170e093a-3fe7-415b-a742-0458650cdf6a" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Common Stock, par value $0.01 per share</span></ix:nonNumeric></span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_a570812d-ba48-4d67-8007-15252cebaefe" contextRef="C_170e093a-3fe7-415b-a742-0458650cdf6a" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">HRTX</span></ix:nonNumeric></span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">The </span><span><ix:nonNumeric id="F_ae253cd6-1246-4868-bb1b-80a95c9b9e07" contextRef="C_170e093a-3fe7-415b-a742-0458650cdf6a" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Nasdaq</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">&#160;Capital Market</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Emerging growth company  </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ad520a0a-5101-45f2-a7f4-294a2ead06dc" contextRef="C_170e093a-3fe7-415b-a742-0458650cdf6a" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  &#9744;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1.5pt double #000000;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 2.02 Results of Operations and Financial Condition.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On November 12, 2024, Heron Therapeutics, Inc. (&#8220;Company&#8221;) issued a press release announcing its financial results for the three and nine months ended September 30, 2024 (&#8220;Earnings Press Release&#8221;). A copy of the Earnings Press Release is furnished as Exhibit 99.1.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This Item 2.02 and the Earnings Press Release attached hereto as Exhibit 99.1, insofar as they disclose information regarding the Company&#8217;s results of operations or financial condition for the three and nine months ended September 30, 2024, are being furnished to the Securities and Exchange Commission.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 9.01 Financial Statements and Exhibits.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(d) Exhibits.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:10%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:89%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Exhibit No.</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Description</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">99.1</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="hrtx-ex99_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Earnings Press Release, dated November 12, 2024</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">104</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SIGNATURES</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:49%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:49%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Heron Therapeutics, Inc.</span></p></td>
   </tr>
   <tr style="height:12.25pt;white-space:pre-wrap;word-break:break-word;">
    <td colspan="4" style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date: November 12, 2024</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;border-bottom:0.75pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Ira Duarte</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Ira Duarte</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Executive Vice President, Chief Financial Officer</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>hrtx-ex99_1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html>
 <head>
  <title>EX-99.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;line-height: 1;">
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 99.1</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14pt;font-family:Arial;min-width:fit-content;">Heron Therapeutics Announces Third Quarter 2024 Financial Results and Narrows Financial Guidance</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Reported positive YTD 2024 Adjusted EBITDA of $1.4 million</font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Company expects Q4 2024 Net Revenue in the range of $37 million - $43 million</font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">ZYNRELEF</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Arial;font-style:italic;min-width:fit-content;">&#174;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> (bupivacaine and meloxicam) extended-release solution Vial Access Needle (&#x201c;VAN&#x201d;) approved in September and on track for Q4 2024 launch</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">CMS Final Rule Non-Opioid Policy for Pain Relief includes ZYNRELEF as a qualifying product for separate payment in both the hospital outpatient department and ambulatory surgical center settings of care</font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">SAN DIEGO, November 12, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (&#x201c;Heron&#x201d; or the &#x201c;Company&#x201d;), a commercial-stage biotechnology company, today announced financial results for the three and nine months ended September 30, 2024, and highlighted recent corporate updates.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#x201c;We are pleased to report that with our prudent financial management and continued revenue growth we were able to achieve positive Adjusted EBITDA for the quarter,&#x201d; said Craig Collard, Chief Executive Officer. &#x201c;The future looks bright as we continue to grow all product revenue. The CrossLink partnership roll out, FDA approval of the VAN in September, and inclusion in the CMS Final Rule Non-Opioid Policy for Pain Relief, positions ZYNRELEF for significant growth within the surgical setting.&#x201d;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#x201c;We continue to deliver on our commitment to financial efficiency while growing revenue. The team has made great strides in the transformation of Heron over the past year. We are looking forward to a strong fourth quarter which is off to a great start. As such, we are narrowing guidance for full-year 2024.&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Financial Guidance for 2024</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The Company narrows its full-year 2024 guidance for Product Revenues, Net, Adjusted Operating Expenses and Adjusted EBITDA:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:26.875%;box-sizing:content-box;"></td>
    <td style="width:24.375%;box-sizing:content-box;"></td>
    <td style="width:24.375%;box-sizing:content-box;"></td>
    <td style="width:24.375%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-top:1.5pt double;border-left:1.5pt double;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-top:1.5pt double;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Original</font></p></td>
    <td style="border-top:1.5pt double;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Q2 Updated Guidance</font></p></td>
    <td style="border-top:1.5pt double;border-right:1.5pt double;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Q3 Updated Guidance</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-left:1.5pt double;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Product Revenues, Net</font></p></td>
    <td colspan="2" style="border-right:0.5pt dotted;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt dotted;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">$138.0 to $158.0 million</font></p></td>
    <td style="border-right:1.5pt double;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt dotted;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">$140.0 to $146.0 million</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-left:1.5pt double;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Adjusted Operating Expenses</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-right:0.5pt dotted;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt dotted;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">$108.0 to $116.0 million</font></p></td>
    <td style="border-right:0.5pt dotted;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt dotted;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">$107.0 to $111.0 million</font></p></td>
    <td style="border-right:1.5pt double;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt dotted;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">$101.0 to $105.0 million</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-left:1.5pt double;padding-left:0.075in;vertical-align:top;border-bottom:1.5pt double;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Adjusted EBITDA</font></p></td>
    <td style="border-right:0.5pt dotted;padding-left:0.075in;vertical-align:top;border-bottom:1.5pt double;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">$(22.0) to $3.0 million</font></p></td>
    <td style="border-right:0.5pt dotted;padding-left:0.075in;vertical-align:top;border-bottom:1.5pt double;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">$(10.0) to $3.0 million</font></p></td>
    <td style="border-right:1.5pt double;padding-left:0.075in;vertical-align:top;border-bottom:1.5pt double;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">$2.0 to $5.0 million</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Business Highlights</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">The ZYNRELEF VAN will be available for initial use in the fourth quarter </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">following approval by the U.S. Food and Drug Administration (&#x201c;FDA&#x201d;) on September 24, 2024. The VAN will replace the current vented vial spike and has the potential to simplify aseptic preparation, while also significantly reducing ZYNRELEF&#x2019;s withdrawal time down to between twenty and forty-five seconds.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">ZYNRELEF will continue to receive separate payment from April 1, 2025, until at least the end of 2027</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> as the result of inclusion in the &#x201c;CMS OPPS and ASC Final Rule CY 2025 Non-Opioid Policy for Pain Relief&#x201d; by the Centers for Medicare &amp; Medicaid Services (&#x201c;CMS&#x201d;). The payment limitation for ZYNRELEF is set at $2,267.26, in line with similar products, and it will be granted the status indicator of &#x201c;K1&#x201d; &#x2013; for Non-Opioid Drugs and Biologicals For Post-Surgical Pain Relief. The goal of the policy is to ensure there are no financial incentives to use opioids </font></div></div>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7.5pt;font-family:Arial;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7.5pt;font-family:Arial;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">instead of non-opioid alternatives like ZYNRELEF. To qualify under the new policy, ZYNRELEF needed to meet strict criteria establishing that it does not act upon the body&#x2019;s opioid receptors and that it successfully demonstrated the ability to replace, reduce, or avoid intraoperative or postoperative opioid requirements in clinical trials or peer reviewed literature. These criteria set a strong precedent from CMS that we expect other payors to follow.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Cash and Cash Equivalents were $70.9 million </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">as of September 30, 2024</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">,</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> compared with $80.4 million on December 31, 2023.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Acute Care Franchise</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Acute Care Franchise Net Product Sales: </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">For the three and nine months ended September 30, 2024, acute care franchise Net Product Sales were $7.4 million and $19.7 million, respectively, compared to $4.7 million and $12.9 million, respectively, for the same period in 2023.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">ZYNRELEF Net Product Sales: </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Net Product Sales of ZYNRELEF for the three and nine months ended September 30, 2024 were $6.3 million and $17.1 million, respectively, compared to $4.4 million and $12.0 million, respectively, for the same period in 2023.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">APONVIE</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Arial;font-style:italic;min-width:fit-content;">&#174;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;"> Net Product Sales:</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Net Product Sales of APONVIE for the three and nine months ended September 30, 2024 were $1.1 million and $2.6 million, respectively, compared to $0.3 million and $0.9 million, respectively, for the same period in 2023.</font></div></div>
  <p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Oncology Care Franchise</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Oncology Care Franchise Net Product Sales:</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> For the three and nine months ended September 30, 2024, oncology care franchise Net Product Sales were $25.4 million and $83.8 million, respectively, compared to $26.7 million and $79.9 million for the same period in 2023.</font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">CINVANTI</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Arial;font-style:italic;min-width:fit-content;">&#174;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:6.7pt;font-family:Arial;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Net Product Sales:</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> Net Product Sales of CINVANTI (aprepitant) injectable emulsion for the three and nine months ended September 30, 2024 were $22.6 million and $73.2 million, compared to $23.3 million and $70.6 million for the same period in 2023.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">SUSTOL</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Arial;min-width:fit-content;">&#174;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Net Product Sales:</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> Net Product Sales of SUSTOL (granisetron) extended-release injection for the three and nine months ended September 30, 2024 were $2.8 million and $10.6 million, respectively, compared to $3.4 million and $9.3 million, respectively, for the same period in 2023.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Conference Call and Webcast</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Heron will host a conference call and live webcast on Tuesday, November 12, 2024, at 8:00 a.m. ET. The conference call can be accessed by phone by utilizing the following registration link which will provide participants with dial-in details. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. The conference call will also be available via webcast under the Investor Relations section of Heron&#x2019;s website at www.herontx.com. An archive of the teleconference and webcast will also be made available on Heron&#x2019;s website for sixty days following the call.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#1e1e1e;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">About ZYNRELEF for Postoperative Pain</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">ZYNRELEF is the first and only dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of nonsteroidal anti-inflammatory drug meloxicam. ZYNRELEF is the first and only extended-release local anesthetic to demonstrate in Phase 3 studies significantly reduced pain and significantly increased proportion of patients requiring no opioids through the first 72 hours following surgery compared to bupivacaine solution, the current standard-of-care local anesthetic for postoperative pain control. ZYNRELEF was initially approved by the FDA in May 2021 for use in adults for soft tissue or periarticular instillation to produce postsurgical analgesia for up to 72 hours after</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </font></p>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">2</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">bunionectomy, open inguinal herniorrhaphy and total knee arthroplasty. In December 2021, the FDA approved an expansion of ZYNRELEF&#x2019;s indication to include foot and ankle, small-to-medium open abdominal, and lower extremity total joint arthroplasty surgical procedures. On January 23, 2024, the FDA approved ZYNRELEF for soft tissue and orthopedic surgical procedures including foot and ankle, and other procedures in which direct exposure to articular cartilage is avoided. Safety and efficacy have not been established in highly vascular surgeries, such as intrathoracic, large multilevel spinal, and head and neck procedures.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Please see full prescribing information, including Boxed Warning, at www.ZYNRELEF.com.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#1e1e1e;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">About APONVIE for Postoperative Nausea and Vomiting (PONV)</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">APONVIE is a substance NK</font><font style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:Arial;min-width:fit-content;">1</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> Receptor Antagonist (RA), indicated for the prevention of PONV in adults. Delivered via a 30-second IV push, APONVIE 32 mg was demonstrated to be bioequivalent to oral aprepitant 40 mg with rapid achievement of therapeutic drug levels. APONVIE is the same formulation as Heron&#x2019;s approved drug product CINVANTI. APONVIE is supplied in a single-dose vial that delivers the full 32 mg dose for PONV. APONVIE was approved by the FDA in September 2022 and became commercially available in the U.S. on March 6, 2023.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#1e1e1e;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Please see full prescribing information at </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">www.APONVIE.com</font><font style="color:#1e1e1e;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#1e1e1e;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">About CINVANTI for Chemotherapy Induced Nausea and Vomiting (CINV) Prevention</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">CINVANTI, in combination with other antiemetic agents, is indicated in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin as a single-dose regimen, delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC) as a single-dose regimen, and nausea and vomiting associated with initial and repeat courses of MEC as a 3-day regimen. CINVANTI is an IV formulation of aprepitant, an NK</font><font style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:Arial;min-width:fit-content;">1</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> RA. CINVANTI is the first IV formulation to directly deliver aprepitant, the active ingredient in EMEND</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Arial;min-width:fit-content;">&#174;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> capsules. Aprepitant (including its prodrug, fosaprepitant) is a single-agent NK</font><font style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:Arial;min-width:fit-content;">1</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> RA to significantly reduce nausea and vomiting in both the acute phase (0&#x2013;24 hours after chemotherapy) and the delayed phase (24&#x2013;120 hours after chemotherapy). The FDA-approved dosing administration included in the U.S. prescribing information for CINVANTI include 100 mg or 130 mg administered as a 30-minute IV infusion or a 2-minute IV injection.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Please see full prescribing information at www.CINVANTI.com</font><font style="color:#1e1e1e;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#1e1e1e;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">About SUSTOL for CINV Prevention</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">SUSTOL is indicated in combination with other antiemetics in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (MEC) or anthracycline and cyclophosphamide (AC) combination chemotherapy regimens. SUSTOL is an extended-release, injectable 5-hydroxytryptamine type 3 RA that utilizes Heron&#x2019;s Biochronomer</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Arial;min-width:fit-content;">&#174;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> drug delivery technology to maintain therapeutic levels of granisetron for &#x2265;5 days. The SUSTOL global Phase 3 development program was comprised of two, large, guideline-based clinical studies that evaluated SUSTOL&#x2019;s efficacy and safety in more than 2,000 patients with cancer. SUSTOL&#x2019;s efficacy in preventing nausea and vomiting was evaluated in both the acute phase (0&#x2013;24 hours after chemotherapy) and delayed phase (24&#x2013;120 hours after chemotherapy).</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Please see full prescribing information at www.SUSTOL.com</font><font style="color:#1e1e1e;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#1e1e1e;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">About Heron Therapeutics, Inc.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#1e1e1e;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Heron Therapeutics, Inc. is</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care. Our advanced science, patented technologies, and innovative approach to drug discovery and development have allowed us to create and commercialize a portfolio of products that aim to advance the standard-of-care for acute care and oncology patients. </font><font style="color:#1e1e1e;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">For more information, visit </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">www.herontx.com</font><font style="color:#1e1e1e;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">.</font></p>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">3</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Non-GAAP Financial Measures</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">To supplement our financial results presented on a GAAP basis, we have included information about certain non-GAAP financial measures. We believe the presentation of these non-GAAP financial measures, when viewed with our results under GAAP, provide analysts, investors, lenders, and other third parties with insights into how we evaluate normal operational activities, including our ability to generate cash from operations, on a comparable year-over-year basis and manage our budgeting and forecasting.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">In our quarterly and annual reports, earnings press releases and conference calls, we may discuss the following financial measures that are not calculated in accordance with GAAP, to supplement our consolidated financial statements presented on a GAAP basis.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#222222;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Adjusted EBITDA</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#222222;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Adjusted EBITDA is a non-GAAP financial measure that represents GAAP net income or loss adjusted to exclude interest expense, interest income, the benefit from or provision for income taxes, depreciation, amortization, stock-based compensation, and other adjustments to reflect changes that occur in our business but do not represent ongoing operations. Adjusted EBITDA, as used by us, may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#222222;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">There are several limitations related to the use of adjusted EBITDA rather than net income or loss, which is the nearest GAAP equivalent, such as:</font></p>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#222222;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#222222;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">adjusted EBITDA excludes depreciation and amortization and, although these are non-cash expenses, the assets being depreciated or amortized may have to be replaced in the future, the cash requirements for which are not reflected in adjusted EBITDA;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#222222;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#222222;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">we exclude stock-based compensation expense from adjusted EBITDA although: (i) it has been, and will continue to be for the foreseeable future, a significant recurring expense for our business and an important part of our compensation strategy; and (ii) if we did not pay out a portion of our compensation in the form of stock-based compensation, the cash salary expense included in operating expenses would be higher, which would affect our cash position;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#222222;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#222222;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">we exclude impairment of long-lived assets, the amount and/or frequency of which are not part of our underlying business.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#222222;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#222222;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">we exclude inventory write-downs (and write-ups should they occur), the amount and/or frequency of which are not part of our underlying business.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#222222;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#222222;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">adjusted EBITDA does not reflect changes in, or cash requirements for, working capital needs;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#222222;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#222222;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">adjusted EBITDA does not reflect the benefit from or provision for income taxes or the cash requirements to pay taxes;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#222222;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#222222;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">adjusted EBITDA does not reflect historical cash expenditures or future requirements for capital expenditures or contractual commitments; and </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#222222;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#222222;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">we exclude restructuring expenses from adjusted EBITDA. Restructuring expenses primarily include employee severance and contract termination costs that are not related to acquisitions. The amount and/or frequency of these restructuring expenses are not part of our underlying business.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Adjusted Operating Expenses</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Adjusted operating expenses is a non-GAAP financial measure that represents GAAP operating expenses adjusted to exclude stock-based compensation expense, depreciation and amortization, and other adjustments to reflect changes that occur in our business but do not represent ongoing operations.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#222222;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The Company has not provided a reconciliation of its full-year 2024 guidance for adjusted EBITDA or adjusted operating expenses to the most directly comparable forward-looking GAAP measures, in reliance on the unreasonable efforts exception provided under Item 10(e)(1)(i)(B) of Regulation S-K, because the Company is unable to predict, without unreasonable efforts, the timing and amount of items that would be included in such a reconciliation, including, but not limited to, stock-based compensation expense, acquisition related expense and litigation settlements. These items are uncertain and depend on various factors that are outside of the Company&#x2019;s control or cannot be reasonably predicted. While</font><font style="color:#222222;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </font></p>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">4</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#222222;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">the Company is unable to address the probable significance of these items, they could have a material impact on GAAP net income and operating expenses for the guidance period.</font><font style="color:#222222;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#1e1e1e;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Forward-looking Statements</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#1e1e1e;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">This news release contains &#x201c;forward-looking statements&#x201d; as defined by the Private Securities Litigation Reform Act of 1995. Heron cautions readers that forward-looking statements are based on management&#x2019;s expectations and assumptions as of the date of this news release and are subject to certain risks and uncertainties that could cause actual results to differ materially. Therefore, you should not place undue reliance on forward-looking statements. Examples of forward-looking statements include, among others, statements we make regarding the potential market opportunities for ZYNRELEF, APONVIE, CINVANTI and SUSTOL; revenue, adjusted EBITDA and other financial guidance provided by the Company; the results of the commercial launch of APONVIE; the potential additional market opportunity for the expanded U.S. label for ZYNRELEF or inclusion of ZYNRELEF under the OPPS and the ASC payment system; the timing of the Company&#x2019;s development of the VAN program and receipt of required regulatory approvals; our ability to establish and maintain successful commercial arrangements like our co-promotion agreement with </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">CrossLink Life Sciences, LLC (&#x201c;CrossLink&#x201d;)</font><font style="color:#1e1e1e;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">; the outcome of the Company&#x2019;s pending ANDA litigation; whether the Company is required to write-off any additional inventory in the future; the expected future balances of Heron&#x2019;s cash, cash equivalents and short-term investments; the expected duration over which Heron&#x2019;s cash, cash equivalents and short-term investments balances will fund its operations and the risk that future equity financings may be needed; any inability or delay in achieving profitability. Important factors that could cause actual results to differ materially from those in the forward-looking statements are set forth in our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q, and in our other reports filed with the Securities and Exchange Commission, including under the caption &#x201c;Risk Factors.&#x201d; Forward-looking statements reflect our analysis only on their stated date, and Heron takes no obligation to update or revise these statements except as may be required by law.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">5</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Heron Therapeutics, Inc.</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Consolidated Statements of Operations</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="range_a1_e13"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Arial;min-width:fit-content;"> (In thousands, except per share amounts)</font><font id="range_a1_i17"></font><font id="range_a1_i18"></font><font id="range_a1_i13"></font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="range_a1_i19"><font id="range_a1_e14"></font><font id="range_a1_e19"></font><font id="range_a1_i14"></font><font id="range_a1_i15"></font>&#160;</p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="range_a1_i16"><font id="range_a1_e17">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:97.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:39.476%;box-sizing:content-box;"></td>
    <td style="width:2.165%;box-sizing:content-box;"></td>
    <td style="width:13.214%;box-sizing:content-box;"></td>
    <td style="width:2.659%;box-sizing:content-box;"></td>
    <td style="width:13.214%;box-sizing:content-box;"></td>
    <td style="width:2.659%;box-sizing:content-box;"></td>
    <td style="width:12.224%;box-sizing:content-box;"></td>
    <td style="width:2.577%;box-sizing:content-box;"></td>
    <td style="width:11.812%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:14.4pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="3" style="padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Three months ended September 30,</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="3" style="padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Nine months ended September 30,</font></p></td>
   </tr>
   <tr style="height:14.4pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2024</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2023</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2024</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2023</font></p></td>
   </tr>
   <tr style="height:14.4pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.296%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Revenues:</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="7" style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(unaudited)</font></p></td>
   </tr>
   <tr style="height:14.4pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.296%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Net product sales</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;$ 32,810</font><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;$ 31,434</font><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;$ 103,504</font><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;$ 92,811</font><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:14.4pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.296%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Cost of product sales</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;9,458</font><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;18,208</font><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;28,420</font><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;55,220</font><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:14.4pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.296%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Gross Profit</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-top:0.5pt solid;padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;23,352</font><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="border-top:0.5pt solid;padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="border-top:0.5pt solid;padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;13,226</font><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="border-top:0.5pt solid;padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="border-top:0.5pt solid;padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;75,084</font><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="border-top:0.5pt solid;padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="border-top:0.5pt solid;padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;37,591</font><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:14.4pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.296%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Operating expenses:</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:14.4pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.296%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Research and development</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;4,465</font><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;9,285</font><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;13,505</font><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;31,331</font><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:14.4pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.296%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">General and administrative</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;12,373</font><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;15,914</font><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;41,252</font><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;51,340</font><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:14.4pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.296%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Sales and marketing</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;10,972</font><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;12,956</font><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;36,028</font><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;55,315</font><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:14.4pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.296%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Total operating expenses</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;27,810</font><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;38,155</font><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;90,785</font><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;&#160;&#160;&#160;137,986</font><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:14.4pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.296%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Loss from operations</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(4,458)</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;(24,929)</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;(15,701)</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;&#160;&#160;(100,395)</font></p></td>
   </tr>
   <tr style="height:14.4pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.296%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Other (expense) income, net</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(390)</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(79)</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;(1,542)</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;560</font><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:14.4pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.296%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Net loss</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;$ (4,848)</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;$ (25,008)</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;$ (17,243)</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;$ (99,835)</font></p></td>
   </tr>
   <tr style="height:15.1pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.296%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Basic and diluted net loss per share</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;border-bottom:2.25pt double;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;$ (0.03)</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;border-bottom:2.25pt double;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;$ (0.17)</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;border-bottom:2.25pt double;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;$ (0.11)</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;border-bottom:2.25pt double;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">$ (0.75)</font></p></td>
   </tr>
   <tr style="height:15.1pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.296%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Weighted average common shares outstanding, basic and diluted</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;border-bottom:2.25pt double;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;152,830</font><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;border-bottom:2.25pt double;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;144,990</font><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;border-bottom:2.25pt double;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;&#160;&#160;&#160;152,213</font><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;border-bottom:2.25pt double;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;&#160;&#160;&#160;133,747</font><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">6</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Heron Therapeutics, Inc.</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Consolidated Balance Sheets</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">(in thousands)</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="range_a1_e32"><font id="range_a1_e35"></font><font id="range_a1_e36"></font>&#160;</p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:88.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:59.8%;box-sizing:content-box;"></td>
    <td style="width:18.98%;box-sizing:content-box;"></td>
    <td style="width:2.84%;box-sizing:content-box;"></td>
    <td style="width:18.38%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:32.4pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">September 30,<br>2024</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;padding-right:0.075in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">December 31,<br>2023</font></p></td>
   </tr>
   <tr style="height:14.4pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">(Unaudited)</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:14.4pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">ASSETS</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:14.4pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Current assets:</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:14.4pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:4.08%;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Cash and cash equivalents</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">$ 25,741</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">$ 28,677</font><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:14.4pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:4.08%;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Short-term investments</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;&#160;45,149</font><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">51,732</font><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:14.4pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:4.08%;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Accounts receivable, net</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;&#160;67,039</font><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">60,137</font><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:14.4pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:4.08%;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Inventory</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;&#160;45,950</font><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">42,110</font><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:14.4pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:4.08%;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Prepaid expenses and other current assets</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;&#160;11,308</font><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;padding-right:0.075in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">6,118</font><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:14.4pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:8.147%;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Total current assets</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;&#160;195,187</font><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">188,774</font><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:14.4pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Property and equipment, net</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;&#160;15,414</font><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">20,166</font><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:14.4pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Right-of-use lease assets</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;&#160;3,469</font><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">5,438</font><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:14.4pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Other assets</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;&#160;6,707</font><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">8,128</font><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:15.1pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:8.147%;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Total assets</font></p></td>
    <td style="border-top:0.5pt solid;padding-left:0.075in;vertical-align:bottom;border-bottom:2.25pt double;padding-right:0.075in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">$ 220,777</font><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="border-top:0.5pt solid #ffffff03;padding-left:0.075in;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;padding-right:0.075in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-top:0.5pt solid;padding-left:0.075in;vertical-align:bottom;border-bottom:2.25pt double;padding-right:0.075in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">$ 222,506</font><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:15.1pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">LIABILITIES AND STOCKHOLDERS&#x2019; DEFICIT</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:14.4pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Current liabilities:</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:14.4pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:4.08%;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Accounts payable</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">$ 10,188</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">$ 3,240</font><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:14.4pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:4.08%;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Accrued clinical and manufacturing liabilities</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;&#160;22,859</font><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">22,291</font><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:14.4pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:4.08%;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Accrued payroll and employee liabilities</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;&#160;8,531</font><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">9,224</font><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:14.4pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:4.08%;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Other accrued liabilities</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;&#160;40,717</font><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">41,855</font><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:14.4pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:4.08%;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Current lease liabilities</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;&#160;3,249</font><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">3,075</font><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:14.4pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:8.147%;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Total current liabilities</font></p></td>
    <td style="border-top:0.5pt solid;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;&#160;85,544</font><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="border-top:0.5pt solid #ffffff03;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-top:0.5pt solid;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">79,685</font><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:14.4pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:4.08%;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Non-current lease liabilities</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;&#160;522</font><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">2,800</font><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:14.4pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:4.08%;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Non-current notes payable, net</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;&#160;24,828</font><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">24,263</font><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:14.4pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:4.08%;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Non-current convertible notes payable, net</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;&#160;149,647</font><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">149,490</font><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:14.4pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:4.08%;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Other non-current liabilities</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;&#160;241</font><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;padding-right:0.075in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">241</font><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:14.4pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:8.147%;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Total liabilities</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;&#160;260,782</font><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;padding-right:0.075in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">256,479</font><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:14.4pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Stockholders&#x2019; deficit:</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:14.4pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:4.08%;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Common stock</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;&#160;1,517</font><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">1,503</font><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:14.4pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:4.08%;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Additional paid-in capital</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;&#160;1,881,695</font><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">1,870,525</font><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:14.4pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:4.08%;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Accumulated other comprehensive (loss) income</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;&#160;40</font><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">13</font><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:14.4pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:4.08%;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Accumulated deficit</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;&#160;(1,923,257)</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;padding-right:0.075in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(1,906,014)</font></p></td>
   </tr>
   <tr style="height:14.4pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:8.147%;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Total stockholders&#x2019; deficit</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;&#160;(40,005)</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;padding-right:0.075in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(33,973)</font></p></td>
   </tr>
   <tr style="height:15.1pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:8.147%;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Total liabilities and stockholders&#x2019; deficit</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;border-bottom:2.25pt double;padding-right:0.075in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">$ 220,777</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;padding-right:0.075in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;border-bottom:2.25pt double;padding-right:0.075in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">$ 222,506</font><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="range_a1_e33">&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="range_a1_e34">&#160;</p>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">7</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Investor Relations and Media Contact:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Ira Duarte<br>Executive Vice President, Chief Financial Officer<br>Heron Therapeutics, Inc.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">iduarte@herontx.com</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">858-251-4400</font></p>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">8</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>hrtx-20241112.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2024-11-11T19:30:21.0383+00:00 -->
<!-- Copyright (c) 2024 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://www.herontx.com/20241112" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:hrtx="http://www.herontx.com/20241112">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" namespace="http://xbrl.sec.gov/dei/2024"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" namespace="http://fasb.org/us-gaap/2024"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.herontx.com/20241112/taxonomy/role/Role_DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbase id="lnk">
        <link:roleRef roleURI="http://www.herontx.com/20241112/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:href="hrtx-20241112.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
        <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12b Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SolicitingMaterial_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SolicitingMaterial_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_WrittenCommunications_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_WrittenCommunications_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Issuer Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Securities Act File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
        </link:labelLink>
        <link:presentationLink xlink:role="http://www.herontx.com/20241112/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="49.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="50.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="51.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="52.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="53.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="54.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="55.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="56.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="57.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="58.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="59.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="60.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="61.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="62.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="63.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="64.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="65.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="66.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="67.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="68.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="69.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="70.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="71.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
      </link:linkbase>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>5
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45262904621008">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Nov. 12, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Heron Therapeutics, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000818033<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Nov. 12,  2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-33221<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">94-2875566<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">4242 Campus Point Court<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Diego<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92121<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(858)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">251-4400 <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12b Security</a></td>
<td class="text">Common Stock, par value $0.01 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">HRTX<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>6
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M.DPC#ZU4.<(Q2[BJT*Y."1ON#J5SI4NC8E.+<$QI-E8%AA.CJN)&6%K[]HX
M#(/:58-3$.]E@INM2.>@&YV4%@F"\+S5XCRDD/:,/CP%:29>V6.,@94+&6VG
MC@"D):_:Y[QWV>ETNQ1A[?0A:=3OA*,X1IM&^]M=L$_8CGW)&J-Y1++-VYR-
M19H7ADV4Q.6,RT-;"K<V_O DYV_&G6U4(RXM.2TD+F*LJ"C VO9#VJ^_!1R[
M.]PA,[5I3NQ'THC(V*V$I:+@ZA00TA[^+5RU?R=:K646-4>;UAR/*+0Z*X0G
MI84*;:*,Q?3PA\P/FLH1Q2L>TKNX3@TA;>YE#$=8?Q]&H05^['5Z/U$H=8((
M:5__I"*<E<E*9:3'D2+-Q1GOA.?M=A PBK/.%B%MZ5^Q]K&0X82E:9'M3,\T
MLM)"Q\H.7J<'3CO[5"4RDE9F2_89E[V6(FFL:VF5HSQU;N"TD4\TE-,#N.^V
ME0<6:%AV?UDLFJ-Z1.\HV5[U3QOX?\@>C2F0["@@+7L4L,X"G+;LF;28X]4"
M*YPY>Z^T&XEH'3?(LHQ1T<L9RX5F:Y$4P+X/+H*0Y3A6LQ*:9*X3 Z>=?*9%
M[-;>]"V=J^:51PL\/,]^ITCJ+,!/R@)W*>BE(_J "G;E(IZ+K'D:_^?1P-\[
M([O?&SX+]T;#$EB@4'!QB;IZ>X3?WEB5E\?FN;)X""\O5R!PT;D&^/U"*?M^
MXT[BU0\IPW\ 4$L#!!0    ( -% ;%F?H!OPL0(  .(,   -    >&PO<W1Y
M;&5S+GAM;-U7;6O;,!#^*T(_8&YB:N*1&+9 8;"-0O-A7Y58=@1Z\62Y<_KK
MI[-L)VEU9=V'L<VAR=T]NKM'=R>9KEMWDOSAR+DCO9*ZW="C<\W[)&D/1ZY8
M^\XT7'ND,E8QYU5;)VUC.2M;<%(R6=[<9(EB0M-BK3MUIUQ+#J;3;D-O:%*L
M*Z//EI0&@U_*%">/3&[HEDFQMV)8RY20IV!>@N%@I+'$>2I\0Q=@:9\"O @:
ML!SC**&-!6,2,H3O_;C\&3!IK5>%E#/!)0V&8MTPY[C5=UX9%@_&%Q 9Y=VI
M\0QKRTZ+Y2T].PP_/LG>V)+;.<V"3J9B+7D%=*RHC_#K3), Z)Q17B@%JXUF
M X?)8Q1\V .7\@%:^*VZBMU7)/3B4PEM(+#52?2$1C&$"0K$OXP68E^$O?VM
ML*01C\9][/QN]*!_[XSC]Y97HA_TOIKS8]$7>'36-/+T08I:*Q[V_LL)BS6;
M_,C16/'DL\&D'+R!6TH>N77B<&GY85FSX[V;IJFO<,[+?Y#SGZUSS36W3%Z2
M]J/_-U?Y+8R3\?1<'-&K SI;"5R$&_H5[E=YYD#VG9!.Z%$[BK+D^L4Y]>$=
MV_L+_"J^7U_RBG72[69P0\_R%UZ*3N7SJGNHR[CJ+'^&^VB1S;>PSR5TR7M>
M;D?5UOM!)%[P6<<'')XC=\,31S"?@,41P+ \& /,)WAA>?ZG_:S0_00,X[:*
M(BO49X7Z!*\8LAT^6)ZX3^Z?^$[S/$VS#*OH=AMEL,7JEF7P%X^&<0,/+ ]D
M>ENM\6[C$_+Z'& ]?6U"L)WBDXCM%*\U(/&Z@4>>Q[N-Y0$/K O8[$#^>!Z8
MJ;A/FD)7,6[8"<:1/,<0F,7XC&894IT,/O'^8*<D3?,\C@ 69Y"F& *G$4<P
M!L !0])T> \^>Q\ETWLJ.?]74_P$4$L#!!0    ( -% ;%F7BKL<P    !,"
M   +    7W)E;',O+G)E;'.=DKENPS ,0'_%T)XP!] AB#-E\18$^0%6H@_8
M$@6*19V_K]JE<9 +&7D]/!+<'FE [3BDMHNI&/T04FE:U;@!2+8ECVG.D4*N
MU"P>-8?20$3;8T.P6BP^0"X99K>]9!:G<Z17B%S7G:4]VR]/06^ KSI,<4)I
M2$LS#O#-TG\R]_,,-47E2B.56QIXT^7^=N!)T:$B6!::1<G3HAVE?QW']I#3
MZ:]C(K1Z6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ T4!L61PX
M9>H_ 0  / (   \   !X;"]W;W)K8F]O:RYX;6R-4<MNPD ,_)75?D 34(M4
M1+B4/I"J%I6*^Y)UB,4^(J\#+5]?)U%4I%YZ\GILC6=F%^=(QWV,1_7E74B%
MKIF;>9:EL@9OTDUL(,BDBN0-2TN'+#4$QJ8:@+W+IGD^R[S!H)>+D6M#V743
M&4K&& 3L@!W".?W.NU:=,.$>'?)WH?NW ZT\!O1X 5OH7*M4Q_-+)+S$P,9M
M2XK.%7HR#'9 C.4?>-N)_#3[U"-L]A]&A!1ZE@MAA92XW^CYC6@\@2P/7<OQ
M"1T#K0S#,\6VP7#H:,1%=F6CSV&L0XAS^D^,L:JPA%4L6P^!AQP)7"<PI!J;
MI%4P'@H]KB@3K'H,+"&I=1BH9+=S*J?7=G#-(O<J0YJC#&AM!^&C6@L5!K!O
M<B )+LF5&U)=Z7FFMW>3>TFH=>Y!L/?P&HT=S8\?M_P!4$L#!!0    ( -%
M;%DD'INBK0   /@!   :    >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'.U
MD3T.@S ,A:\2Y0 U4*E#!4Q=6"LN$ 7S(Q(2Q:X*MR^% 9 Z=&&RGBU_[\E.
MGV@4=VZ@MO,D1FL&RF3+[.\ I%NTBB[.XS!/:A>LXEF&!KS2O6H0DBBZ0=@S
M9)[NF:*<//Y#='7=:7PX_;(X\ \PO%WHJ45D*4H5&N1,PFBV-L%2XLM,EJ*H
M,AF**I9P6B#BR2!M:59]L$].M.=Y%S?W1:[-XPFNWPQP>'3^ 5!+ P04
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MYHOA/UY_ 5!+ 0(4 Q0    ( -% ;%D'04UB@0   +$    0
M  "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ T4!L6=OTY@;N
M    *P(  !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L!
M A0#%     @ T4!L69E<G",0!@  G"<  !,              ( !S $  'AL
M+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " #10&Q9MQF<#VX$  !4$0
M&               @($-"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L!
M A0#%     @ T4!L69^@&_"Q @  X@P   T              ( !L0P  'AL
M+W-T>6QE<RYX;6Q02P$"% ,4    " #10&Q9EXJ[',     3 @  "P
M        @ &-#P  7W)E;',O+G)E;'-02P$"% ,4    " #10&Q9'#AEZC\!
M   \ @  #P              @ %V$   >&PO=V]R:V)O;VLN>&UL4$L! A0#
M%     @ T4!L620>FZ*M    ^ $  !H              ( !XA$  'AL+U]R
M96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ T4!L6660>9(9 0
MSP,  !,              ( !QQ(  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&
2      D "0 ^ @  $10

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="hrtx-20241112.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.herontx.com/20241112/taxonomy/role/Role_DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="hrtx-20241112.htm">hrtx-20241112.htm</File>
    <File>hrtx-20241112.xsd</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>12
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "hrtx-20241112.htm": {
   "nsprefix": "hrtx",
   "nsuri": "http://www.herontx.com/20241112",
   "dts": {
    "inline": {
     "local": [
      "hrtx-20241112.htm"
     ]
    },
    "schema": {
     "local": [
      "hrtx-20241112.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 24,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 23
   },
   "report": {
    "R1": {
     "role": "http://www.herontx.com/20241112/taxonomy/role/Role_DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_170e093a-3fe7-415b-a742-0458650cdf6a",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hrtx-20241112.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_170e093a-3fe7-415b-a742-0458650cdf6a",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hrtx-20241112.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.herontx.com/20241112/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.herontx.com/20241112/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.herontx.com/20241112/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.herontx.com/20241112/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.herontx.com/20241112/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.herontx.com/20241112/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line Two",
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.herontx.com/20241112/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.herontx.com/20241112/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.herontx.com/20241112/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.herontx.com/20241112/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.herontx.com/20241112/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.herontx.com/20241112/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Securities Act File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.herontx.com/20241112/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.herontx.com/20241112/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.herontx.com/20241112/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.herontx.com/20241112/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.herontx.com/20241112/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre Commencement Issuer Tender Offer",
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.herontx.com/20241112/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre Commencement Tender Offer",
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.herontx.com/20241112/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12b Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.herontx.com/20241112/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.herontx.com/20241112/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soliciting Material",
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.herontx.com/20241112/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.herontx.com/20241112/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written Communications",
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>13
<FILENAME>0000950170-24-124626-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-24-124626-xbrl.zip
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MWX*QHTB$H1B@ST'$(B]@(6H5HQ[!-+T*.@M#="U?2]&U2$5R)W@E[[2= 3X
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MR&,]60&EZD+S8YWE,*Y *0 -#^)(Y45=T6:A+XNT9$?*QATVD/FU7@3OJ.Y
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M1NC0C%&Q 0$&BZR">3LKB$0-P<G5AER5H!$6C /LC=9TOYN<:7)D% 35'BI
M:U1HI8]&7T/F$#D&%07@7!FS@*=CO68Z",08%ZV;*8%6!0L!P,9LK"OL<=U_
M"HXW=1<6/KL0&A8)FE\:,UDE'R/RWS1**>AC7CWSD-S;S_RUTP751RFH, DL
M#/:S; JS-WT%\/SNU,NZH+[XN/&::!T"X2AT%R9!9AJ6CQ]#=(> OJR<)2RH
MDBLZ9*8%G[KRF/I3,J(W3/4U&* ;)&]]P)3W5UUW/R4W5.IAM6K*\<XAO&J8
M*$41%>J1B*G/?8? 4S#I&/1 'K(;IOH0YD>A?"O*^\W\KT4P[UN3*Z$I>]!.
MBZT<VB=MV4G&U&6OV(U"^C$?(.F [9C=NNT4*.IG 18K^9T"[XJNG<R'EK<,
M02?:_F%VU$Z-7;JOB@GQ\]ZK#Q0L5*I8SV\@&Y2[XPR??KE_0%E&L&;9C!)M
M((<&Z/KPX9#_N:E@_> 9H7IWY[+LLVDW1,ZCA%X+["Y,SCZ?OW0R)8H%>707
MIL,FP4;M0CC._#954-N4KT^W$ ;8UFL5W9^77/Y&)JD<.3F-U3TROE:>HOE6
M1BJZ,.""Y;U,\#O0#D(R2Y@BC9IZ&Z,[L'?LZ^2/.*Q,==/4_D3XGJ7HME*>
M0*5+P H+1Y\'JY'SI\:9!.M9"&3D.IH:Q_39S-.XYD:4Z602<JWY &(!DPB9
M=G>JCLKS[E#EPD,QI"&A'E.,!X:;C8H 6N% *W1XKGF>XDT#YN.&0"R-6>P;
M]UL>I#&=4553:8$.N!@TL-9BPQ'+Q_8BQK:HT*#:LFNF@FJ2P6'4DAZ8?BN0
ML>A\/%I9GC&+W/%B!-)"<_<IN8QTB&6I=H:OO22?<GFU?]@=-49LA8MD1Z^:
M7A=#ADKR:]<&AOY [J.DI]<8.7-0%,\TE_FPTGT=1O=D0=Q1V2#P1C1#IYL,
MG:B4 @1JDK7PRFZ1P(= *V' 8C%_1.KT/N/VP&4)6!,LS4<-,R9^$7W/?GE[
M\;)@;.);)CJJHCD)5_K(O":!.3"@Y3@;7.U8!&CGL$>L^%=<\>HU*=?,L]<#
MD^@YZI6 3K/1JS-&@'I[A"IE47/#H\P51%S*Z>KSY_.PF@6+%T"FDIO0":@:
MBBJ]= Z&JJ^H2O!$/RZH]1B91H)Z^^O;#V]..K/9IQ.9ANC@/9]9)6<S6N;
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M(]!"D$H5L<_*-_-.#[W5;N>CZ::^YDD>=#?UK6#O(B8:Z2#G>+G6A0OL'+\
M/A@FHZQ+GF1&<XTJRJ0S0D6:X@8I&8;V&++C?&340>-L7&2/U'0YT<7)P,A#
MZL_RNX=I LS3--/#.73G/J/7HC329))IT$9\9*5)<_N<\:1YQ[&E%4LKJ\.)
M+%>>5FDS&=YK=6F1N#*"Z9$S_I)PC!=+U<Y'ZQ2J\2].QZ,T(X(L+Q15#<F8
MTBTR0J#%B@Y =^PPB026KP'>G=.2M$F+(7(@.7P'/3THC[3I6-B&;A-P/>VK
M=\XX+G>(!FW  T5<$Z!5]'CI*+9Q7=T;)J-<$8_Q]]4Z8$[3DH;8PBG;0K'&
MPZAQLPU*<BO2$*OQ54D?BS-!J;^FH+?YQBS&H;,8C*5]2_O/H7T@'\KCK -&
M"%9&!;-8 B/EC,0;BS123<)> 14.452QR)_B&_-2JDB"RG4;3A'%,YI==:6#
M15:+K(]"U@@3F;%1\VV,4P3B%JR2,R5NU!?I1!(Y4@P3\':J[>N7%HDM$I?,
M,@D$ *B@U^=N(0[Z@XB7FP2@$8CX*^*B3[$L. 3KF072J@ 6(3>/D$]SEQ*C
MV=_'6VRT#NJU>LIBJL74S6/JB&,.@,F/SKPU 4^4<QI%O;(P[SM8,B:Z^+RZ
MFH#Z"09+,<N9:R>^MAXM!EL,?H8&B[[N. 7<BN=,_V4.EBKYO/SA2<SAD+F^
M#D2-RL:34$Q9YK3/[F#*$)DD+![G%:UXV\5\=+[@UJ<^$(GV+)CJR ?49NTI
M7;&E9VK3-KR[L]3"#4?K/^:>K;<&%VSD_L#2A_*S7.*E7"N*OV2<95'\;SFB
MG8<#.;N-ON\?!8X:L;<5WB87IHH/PQ5*0.FT4KPI+,:VPSX/>9Z_BAVYL+)9
MIVJJZW&QSE^)6%6RMJ"<%K]:@O0F<#[&*S/S)FJ%1 L8\A:KXD(AE)VOB&>6
M*@NH"K*:J]F%CD:D$5X()B)]"_QPB*E]2$]LHK:0;TXGTEZ"KDC<VAE[>>:^
M/.,OSWY^B;O\S*ZS[FY7E7\ZJB,P!O>3 K@X)N.:;!#,NPNXGS@J?P\C)\N6
MH=UN"1]G::Q&E5!@!9U5$V$>]2A&1W3P?^$\"AFXCJ)2/#V5GJ"XR.JLG!G[
M**@WN=:316?TA:4)OS9!(Y8D6G_7BA#&;]2J4;%)HRPY6A=-H@&!)W(#>IE(
M 65 ZQ)Q0<T"&$G,73:WUAF@SOHUF.O0M.LG,ADX.4BG&<#Q.HW?1SQD#V0!
M;X5P["5DY:[^:YQ0!=*1;\]6_]GJOW(CYQ$JABLU'2 -51VABYO$0'T_RU3Q
MV<P1HM0#1P<>?:75Z X*9 QZ1JSN X<)?'43^F)NLS)<[NN+6<),KG/BC:8B
M>*@(:"?BOX3&3LEK/\O0/N?=@G5QE1?2[!\0IWV\Z]FRP*@B=IM7;BDC FP2
M2;1=X?<7S<E9Y91^(N@3=97.$/2&_**83S&_P6+&*TS!4Z6/Y/W,+/K,5/[;
MN:_L.+?;;59-0R8P&;,L<1JPS/A9O01E%VEC#=[6M8_X0Z&)';!!/\L]5P:D
ME.EX8OXM,V,*Z\/TYT6 J'<PEST=_*EBFB(O:HVY_*H'S6VY)&_2I[FWMH%-
M("@K2%7=S[&&(N?JX539A[J PB%3D68I*,J[@%F_:'VG;,YV7PV7*GE[1\>3
M4'<2>@!^QF!6M2GHFD*_%UZ1.'M"U>Q]5:WV88RL2]%$( 8IGQV-OX(,$A-,
M>TPC?=@H<[*[ZO*;EYQ9OVF$F6[DUB>JLV"*2UA,#LT=<3,/X4R(94X)@W%&
M\/;5/S) F\.=M1DB(86C&N$/9E']A>V@&FOJ=N_M;)K+4G4%*,ZN6FR'=,#"
MN3T3'=H.T\5K0HT/!<?X^.G35=X9_/SJ D/<*H=.3@$*XW[1\['*Y"^V6C+/
M (#S7I.ZWZG/^$3];**7^)WRU6 2E&XI3D/97ZQ(SB_4-'7%ID>F3'T?E)EA
M&A;A2N,8G:(:94+^E9G4UPJ,/A;:TWH=,UV7J0HV=UV#?!$+*=_SZ"MPHB%P
M)MWR"G#]_?L+<I9QN_RIC+F]?&"=6V')^MQ%FNB"EQ4'KZ+-@!CG'X!09AZG
M/E;"F\J9.64T/WHX6)WF)H9#@C\6$'Z6&C=78-#/4%[7#IA0^("&2(B*R!::
MSF($W3%Q]+P:1S-*X&IQ4L%8HBF\-V'QN1F"U#2TQP)WDUCWW"EFZU5)Y<,4
M6YHAB\B=\3DM(ELW@D=O%6= XM=<"*N=35$<IDXQ%( (Y"BC':!]U;Y4ERGC
M[7!X4D (<-#FF2JYS%/.Y_Q\3Y0:.NB;C(1DA=3RAX2E9$J>JCX&BD:5'QF9
M!"SE7%=W?U;5W2AAWJ&<=FN5?YI,^:FZM%"%;Q/RK[PR7+\@BV_\*^L:IR;1
M;-Q4C0,@PZQ/ ZZXH"3@*V_O=( %T7?,I5RX&'7&0'VJ_=,9[7[&<WNGH5G-
ME9-%A;4 CRR@HQB?:@C!<0^P(>T8Y[%^.E#J@=Z0UE,2D(CH^2<"..1U?J=)
M.M%Z!&[UAFOGMV3%*;57'14/@T(Y88(<"^FMC0C97=E=;2Q;Z!'[LU&(<D4A
MFB?D"3WR[=DHA(U"E!LY'RG@6M\2.-MBH!MQV6ZNU_G>X+"6P5_L_#1S4Z.]
M^C$W^O8" \*#'U\H?\D?U/V#N?7G0*7[M"#,V26:-B(%F@FP?Y>V1P >8#>K
MIMDJOT;.NSWFULO=-JSW@9\[#_]<G_V\$ZCG2N;B0KHOEBV0N8V'UL_4:P]L
M[\&WN=O,?\Y8T@(,U,I19D7;%# K@=): 93VX9H':Q@]^MZE)2)?J2-&-< 5
MH*8 :\;'*Z#ZBQ14>'['@KZ>JMNNUK[/G@>R#NE$LIYDF*N7Y'462MKKH95&
M _/GJA+62FF?42][WSP$3P7S)0KU;K71;GU?U&+,/C,UYE42K'C7J[JMYGJO
MNO6JYS;6G;;5[![6M%[5\]:>MMENKSFM6^VXWF/>A0_Q(A89M==M5!M '$L)
MJ%!%HS5M_&()JF4JMB*'6K761DUZX8XP3<RY"1P;G5L_N\)B]7:M6CY!55QR
M*L\&PY(E[]Z0WR1@@#W!0-&/+^HOU@!2;FYEWA+02I3Z5F;PK:W&/S(X'S/,
M\XZ2D23J=D!R!<H:&P] 6ZO7G VBZ$KHD[\-U7^U>IG/837DUU,!+&)O%;$_
MX 663\/KC0JU^R#>D9#K' PSW[*P/QRIMGV"/T("QQJG4DBG\J#?QJ211<CU
M$+)N$=(B9)D0TG)(BY"E0LBE'/+;BO> ^E^O8Y%&0<4LT0=\&_K;=S,!D'=X
M0'/.6J_J=5O??\OO]-@C>]0)?=9YTG/=S ]2:7]:\'>C%GQ['0O^".ST1P'Q
M+(UH&F E_,NMF^"6X!_A)F%)=@DR=H&>ZX%C"7]?SOH9(6X35$L3@#:*71IR
MWY&ZYW3<VG.J,9Y<_7G,9V3Q>=_X[#J->L/BL\7GX\!GMU9WFC6+T!:ACP2A
MNZAPN/O!9^O-*(MQ<X%EAV)H#1S+;[;*;];[L^LTFATK<JW(/2T2<#N.5[-X
M;_'^!/#>ZS@-S_J]+*Z? *XWFXZW+URW8:,=6U;_P!9&Y)-J-V,-JC4YC<D(
M,77D]])!MIOW?4JL:4XDUYUZT]N_2+:';Z%\(%!^LH57!TV@94GL* [?0KDL
M)-9N.K5."6)T]L ME \$RH\AJWK;:79MJ/#$#=J/]^XTL"G0)^Y!L["RL+*P
MLK"RL+*PLK#: JQLU&;GU7V2T=@?F<M \VL]K*9[VA1>FI2XAM-H-??OX3J2
M8[4D<( DT'6\CB4!2P(G0 (N%AU97+>X?@*X7G>=>MU&&4[< /L'BUB,-QGB
M16<!/,5E$JM;0:P)9AG2_A)V/*?>KEM!; 7QB>%]T^FZ)<BH.9*SM'A?8KQO
MN(Y7AKSG(SD_B^LEQO4F&%L-6XIT&C;5%39U,-?'QU\9YG!98ZI\[6Q/E!7-
MJ9LUI]L^+!&\D3M;K)BV5/,LYT2W68)J(DLUEFK*337UEE/S#JNSBJ442RG[
MZ551=_<4>;;1N+)8CE]$0D,B[E7^6//1,JJ2,*KBGU[[X)JH6_%NJ6;/5%/O
M.&[SL)+,+-58JMD#U71K3OO 4H\MI5A*V1&EN/6VT^WLR0]I@XH[-@W?8WO#
M82S&F7DH(FL6VC2&_:FQ9PWL%K_TSKPC!+5%RQ*CY9G7<+I>U^*BQ<4]XN*9
MVW3:-==BH<7"'6/AF5NK.?5N<\T+;&UT9S<J_,=DQ&)R9H(Z+PF/?#%F#HF8
M[7=A70G[%V"/4K7JW=HF)9SUEUDD+QV2SR%\>Z-VA<5WB^][P_<SUVDV/(O.
M%IV/ IU7YM*U;*75:5A4'UA"0B%M(,3Z5S9_8_=9P^DT;(##HMN.T,UK.K6:
MQ3>+;SO"-[?M>(VZQ3>+;[O!MV[7Z=2?'J-H5ET;H]B91OTSE=S7W;AYF"8L
MP.B$TK')A,'9C&AL.\/MW!$ B(">@$"D@Y"=(.N /6Y44#T 7>NXLOBZ 7QU
MVQ9?+;X>$+YN-&_)XJO%URW@J\+4]KHFA+44-GH8ORO@@H%  0STFA%?C,<B
MTB:")")-9 )V! ##(8-%J\*:$)9EE"::Z#8]IU,_Y#IV*V$MN>R.7!H-I]NU
MY&+)Q9++ Q+%<P_K_@)+(I9$=DDB];K3;K3WFZ@%?U,X#?5QFV#^,Y4)'TX?
MC["SZ1^<\;&8C/L+^ WQ0RHEXO UJT0B8-D[L"[\V2SK/Q4>!>RN5ZGWAR&[
MJP0\9CX6G/?@9-)QU ^XG(1TVL-?<TR>Y2QRO3)C?>LO# 2R"=6K%18%_8F0
M7(T=LU#=.P1D<X?[AS%[.07=;9L09N2V#B8N/ZZ'$;-51,SRV*IZ;G=A*S]<
MP%B#F/_@2!K)BF0Q'SZ!D1[Y]EX!\9@_D=)&N0/*+)M'(8]@/0F-DQY-$]&?
M_P'H0'^M"%/[H>@0\+%'PULZE=H?5231C.@4Y!2!%8CV'O&M0V-FA4K,M:JM
M5OO[153?@QRWR+DF<CY2P+6^)7"VQ4!O-;H.1!BLSU%_8;&(R)<1@V%9"@J9
M=,AEY%<7!&&9X;#.MB]$I$H$*#IC?Z8AC7Q&KD:,)?+(=W[&(Y*,1 IT$<B7
M>]DLX<&/+V(:7;,_J/L'JWO9]A>^;\+W155WX>=6_G-&P'H32CU=QI*5N#"L
M&\&)G!P6B(]70#43*:A8_(X%?0VW3J=:^SY['HXDI!/)>I)-: QH,Q]+4$._
M6(REW'#)!SSDR;27O;\D3*)G:W:KG>^+,L8<629DEME5^DVW4^VN^:I7[336
MGK3^J$D?B#'5O=W4=QQ$T.,0RJ6RS2P#F%L*H^*>3'P43[QBDX2-!RPF]9KS
M>A#_Y-6\QBY _A0GT?Z 7VX?D<5@F.H-\PT"NQD"UY\:\7]RM=U]N.Z*.Y\6
MOI<(--O%XK-_1S0-8,Q@^Q46%K-.!#2'V<OI!&36^=75VR]7AX[-AY#5],S
MV:9 =1 !R).$U2$V8=@F 6\TFGJ1QC%\(E1*ELB>97B6B"VL2L_PRJ@4%H]
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MJU$R#G_Z_U!+ 0(4 Q0    ( -% ;%E<-WA:,Q,  %N\   1
M  "  0    !H<G1X+3(P,C0Q,3$R+FAT;5!+ 0(4 Q0    ( -% ;%EI#P]6
M<0D  /%W   1              "  6(3  !H<G1X+3(P,C0Q,3$R+GAS9%!+
M 0(4 Q0    ( -% ;%E]G5^PMS   (;% @ /              "  0(=  !H
D<G1X+65X.3E?,2YH=&U02P4&      ,  P"[    YDT

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>hrtx-20241112_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="hrtx-20241112.xsd" xlink:type="simple"/>
    <context id="C_170e093a-3fe7-415b-a742-0458650cdf6a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818033</identifier>
        </entity>
        <period>
            <startDate>2024-11-12</startDate>
            <endDate>2024-11-12</endDate>
        </period>
    </context>
    <dei:AmendmentFlag
      contextRef="C_170e093a-3fe7-415b-a742-0458650cdf6a"
      id="F_a9eefa1a-66f8-4a82-98af-8792d0ab387c">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="C_170e093a-3fe7-415b-a742-0458650cdf6a"
      id="F_29e16f69-ba01-4e64-9cbe-731e8f4768ad">0000818033</dei:EntityCentralIndexKey>
    <dei:DocumentType
      contextRef="C_170e093a-3fe7-415b-a742-0458650cdf6a"
      id="F_a53982b8-b9b9-4308-b491-a8125b126047">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="C_170e093a-3fe7-415b-a742-0458650cdf6a"
      id="F_3fc7c041-4614-4c22-9b10-fa7c190f07d1">2024-11-12</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="C_170e093a-3fe7-415b-a742-0458650cdf6a"
      id="F_ec68f443-4c4e-4005-955f-5f6fcc03b9e0">Heron Therapeutics, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_170e093a-3fe7-415b-a742-0458650cdf6a"
      id="F_c44b301e-f52b-471d-9aac-3be382b815fb">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="C_170e093a-3fe7-415b-a742-0458650cdf6a"
      id="F_dda70719-5ce2-4b69-ba05-32be4b44f4b1">001-33221</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_170e093a-3fe7-415b-a742-0458650cdf6a"
      id="F_6b8691e5-71d8-4c1e-8aba-fb8035160817">94-2875566</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_170e093a-3fe7-415b-a742-0458650cdf6a"
      id="F_2a0cc5e4-2e77-465f-80ae-422662f9136a">4242 Campus Point Court</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="C_170e093a-3fe7-415b-a742-0458650cdf6a"
      id="F_0ee9f905-8e14-4dc9-a96a-c5bf4411bb0b">Suite 200</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="C_170e093a-3fe7-415b-a742-0458650cdf6a"
      id="F_a629c00e-b2f0-4a11-ae77-c4b6df7f683b">San Diego</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_170e093a-3fe7-415b-a742-0458650cdf6a"
      id="F_2ea9cd90-cf58-45da-bd94-b41d789b13f7">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_170e093a-3fe7-415b-a742-0458650cdf6a"
      id="F_4436cd56-352c-48c1-a9db-40679cd8f08b">92121</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_170e093a-3fe7-415b-a742-0458650cdf6a"
      id="F_5a2485df-ce39-4c03-ae61-530057a17131">(858)</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_170e093a-3fe7-415b-a742-0458650cdf6a"
      id="F_cfea956f-24df-46a0-8b06-f46ba61385ee">251-4400 </dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="C_170e093a-3fe7-415b-a742-0458650cdf6a"
      id="F_00511739-ded9-4c8e-a1f0-1c028f1eea5a">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="C_170e093a-3fe7-415b-a742-0458650cdf6a"
      id="F_ec98dc2a-8064-4d08-98de-9f74cfc7c81e">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="C_170e093a-3fe7-415b-a742-0458650cdf6a"
      id="F_0f8b651a-e4d4-48d8-b458-d555b0a7f3bf">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="C_170e093a-3fe7-415b-a742-0458650cdf6a"
      id="F_eaf9580d-a108-4aa9-8625-6bb2fb875c06">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="C_170e093a-3fe7-415b-a742-0458650cdf6a"
      id="F_12dff7c3-d758-4349-a72b-310336124dbc">Common Stock, par value $0.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_170e093a-3fe7-415b-a742-0458650cdf6a"
      id="F_a570812d-ba48-4d67-8007-15252cebaefe">HRTX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_170e093a-3fe7-415b-a742-0458650cdf6a"
      id="F_ae253cd6-1246-4868-bb1b-80a95c9b9e07">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_170e093a-3fe7-415b-a742-0458650cdf6a"
      id="F_ad520a0a-5101-45f2-a7f4-294a2ead06dc">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
